← Back to all 50 compounds
#42Mitochondrial & Longevity

FOXO4-DRI

senolytic research peptide designed to disrupt FOXO4–p53 interaction

Evidence: animalReviewed 2026-07-25

Investigated uses

  • No adequately documented human investigated use for the exact catalog identity/formulation was identified; any vendor-promoted goals were excluded from evidence grading.

Mechanism and hypotheses

  • FOXO4-DRI was designed to disrupt FOXO4–p53 interaction and selectively induce apoptosis in senescent cells in preclinical models.
  • Hypothesized: Human senolytic efficacy and safety are unknown.

Human evidence

  • Senolytic effects and physical-fitness restoration were reported in aged mice. Limitations: No controlled human administration evidence; senescent-cell targeting may have context-dependent harms.

Safety highlights

  • Unknown or insufficiently characterized for the exact catalog product.
  • Identity, purity, sterility, endotoxin, aggregation, immunogenicity, concentration and route-specific risks are not adequately characterized.

Regulatory context

No FDA-approved product matching the exact catalog presentation was identified in this review.

Sources used for this entry